Neuroendocrine Neoplasms of Head and Neck, Genitourinary and Gynaecological Systems, Unknown Primaries, Parathyroid Carcinomas and Intrathyroid Thymic Neoplasms: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up

Overview

Journal ESMO Open

Publisher Elsevier

Specialty Oncology

Date 2024 Oct 26

PMID 39461777

Authors

J Hadoux

A Lamarca

E Grande

D Deandreis

G Kaltsas

E T Janson

B Tombal

M Pavel

J Thariat

M F van Velthuysen

P Herman

C Dromain

E Baudin

A Berruti

Affiliations

Soon will be listed here.

References

van der Zwan J, Mallone S, van Dijk B, Bielska-Lasota M, Otter R, Foschi R . Carcinoma of endocrine organs: results of the RARECARE project. Eur J Cancer. 2012; 48(13):1923-31. DOI: 10.1016/j.ejca.2012.01.029. View

Merola E, Rinke A, Partelli S, Gress T, Andreasi V, Kollar A . Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?. Ann Surg Oncol. 2019; 27(5):1348-1355. DOI: 10.1245/s10434-019-08049-5. View

Turri-Zanoni M, Maragliano R, Battaglia P, Giovannardi M, Antognoni P, Lombardi D . The clinicopathological spectrum of olfactory neuroblastoma and sinonasal neuroendocrine neoplasms: Refinements in diagnostic criteria and impact of multimodal treatments on survival. Oral Oncol. 2017; 74:21-29. DOI: 10.1016/j.oraloncology.2017.09.010. View

van der Laan T, Plaat B, van der Laan B, Halmos G . Clinical recommendations on the treatment of neuroendocrine carcinoma of the larynx: A meta-analysis of 436 reported cases. Head Neck. 2014; 37(5):707-15. DOI: 10.1002/hed.23666. View

Christakis I, Vu T, Chuang H, Fellman B, Figueroa A, Williams M . The diagnostic accuracy of neck ultrasound, 4D-Computed tomographyand sestamibi imaging in parathyroid carcinoma. Eur J Radiol. 2017; 95:82-88. DOI: 10.1016/j.ejrad.2017.07.026. View

Soga J, Osaka M, Yakuwa Y . Laryngeal endocrinomas (carcinoids and relevant neoplasms): analysis of 278 reported cases. J Exp Clin Cancer Res. 2002; 21(1):5-13. View

Yao J, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E . Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2015; 387(10022):968-977. PMC: 6063317. DOI: 10.1016/S0140-6736(15)00817-X. View

Hong W, Sung M, Chun K, Kim J, Park S, Lee K . Emphasis on the MR imaging findings of brown tumor: a report of five cases. Skeletal Radiol. 2010; 40(2):205-13. DOI: 10.1007/s00256-010-0979-0. View

Hadoux J, Kanaan C, Durand A, Hescot S, Hautefeuille V, Cadiot G . Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and.... Eur J Cancer. 2021; 152:100-115. DOI: 10.1016/j.ejca.2021.04.030. View

10.

Marinelli J, Cass S, Mann S, Haynes D, Hunter J, Isaacson B . Adenomatous Neuroendocrine Tumors of the Middle Ear: A Multi-institutional Investigation of 32 Cases and Development of a Staging System. Otol Neurotol. 2018; 39(8):e712-e721. DOI: 10.1097/MAO.0000000000001905. View

11.

Rozhinskaya L, Pigarova E, Sabanova E, Mamedova E, Voronkova I, Krupinova J . Diagnosis and treatment challenges of parathyroid carcinoma in a 27-year-old woman with multiple lung metastases. Endocrinol Diabetes Metab Case Rep. 2017; 2017. PMC: 5404464. DOI: 10.1530/EDM-16-0113. View

12.

Berner A, Pipinikas C, Ryan A, Dibra H, Moghul I, Webster A . Diagnostic Approaches to Neuroendocrine Neoplasms of Unknown Primary Site. Neuroendocrinology. 2019; 110(7-8):563-573. DOI: 10.1159/000504370. View

13.

MOERTEL C, Kvols L, Oconnell M, Rubin J . Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991; 68(2):227-32. DOI: 10.1002/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i. View

14.

Zatelli M, Torta M, Leon A, Ambrosio M, Gion M, Tomassetti P . Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer. 2007; 14(2):473-82. DOI: 10.1677/ERC-07-0001. View

15.

Villar-Del-Moral J, Jimenez-Garcia A, Salvador-Egea P, Martos-Martinez J, Nuno-Vazquez-Garza J, Serradilla-Martin M . Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study. Surgery. 2014; 156(5):1132-44. DOI: 10.1016/j.surg.2014.05.014. View

16.

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K . Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020; 21(10):1353-1365. DOI: 10.1016/S1470-2045(20)30445-9. View

17.

Wilhelm S, Wang T, Ruan D, Lee J, Asa S, Duh Q . The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg. 2016; 151(10):959-968. DOI: 10.1001/jamasurg.2016.2310. View

18.

Rindi G, Klimstra D, Abedi-Ardekani B, Asa S, Bosman F, Brambilla E . A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018; 31(12):1770-1786. PMC: 6265262. DOI: 10.1038/s41379-018-0110-y. View

19.

Gurizzan C, Zamparini M, Volante M, Tovazzi V, Amoroso V, Consoli F . Outcome of patients with intrathyroidal thymic carcinoma: a pooled analysis. Endocr Relat Cancer. 2021; 28(8):593-604. DOI: 10.1530/ERC-21-0123. View

20.

Pavel M, Oberg K, Falconi M, Krenning E, Sundin A, Perren A . Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(7):844-860. DOI: 10.1016/j.annonc.2020.03.304. View